Page 2 - Drug Makers

Vital medicines' import from India allowed: Pak's drug regulatory authority

Cash-strapped Pakistan's drugs regulatory watchdog has said that hospitals and common citizens can import vital medicines, including anti-cancer drugs and vaccines, from India for their use, a media report said on Friday. The Drug Regulatory Authority of Pakistan (DRAP) said on Thursday that there was no restriction on hospitals or the common man on importing vital medicines (anti-cancer drugs and vaccines) from India for their own use under the Import Policy Order 2022 after obtaining no objection certificate (NOC) from the authority, The News International newspaper reported. The statement of the DRAP officials came during a session of the Senate Standing Committee on Health when Senator Professor Mehr Taj Roghani raised the issue of the unavailability of several essential medicines in the country amidst a financial crisis. In view of (the) unavailability of some essential medicines in Pakistan, common people and hospitals can apply for a NOC to directly import medicines from Indi

India finds 'violations' at cough syrup maker linked to Cameroon deaths

Authorities have stepped up scrutiny of drugmakers after some cough syrups made in India were linked to deaths of dozens of children overseas

CDSCO, states begin joint checks of drug-making units across India

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Role of Maiden Pharma cough syrups in Gambia kids' deaths not confirmed

Indian Health ministry sources say the Haryana-based drug maker is currently being probed for lapses in good manufacturing practices

Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Glenmark Pharma launches Ryaltris nasal spray for allergic rhintis in US

British drugmaker Hikma to distribute Ryaltris while Glenmark will manufacture it

Lupin pharmaceutical inks licensing pact with Japan-based I'rom Group

Drug maker Lupin on Thursday said it has inked a licensing pact with Japan-based I'rom Group Co for a product used in the treatment of postmenopausal women with osteoporosis, among others. Under the terms of the agreement, I'rom along with the Mumbai-based drugmaker will conduct clinical trials, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis. Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumours, among other indications. Following the completion of the clinical trial and receipt of marketing authorisation in Japan, I'rom will commercialise the product in the island nation, Lupin said in a statement. As part of the agreement, the drug maker will receive multiple milestone payments, it added. Currently, Denosumab is available under two brands, Pralia and Ranmark, with market size of about USD 500 mill

India likely to get Omicron-specific vaccine by year-end, says SII chief

SII is working with Novavax to bring the Omicron-specific vaccine, as the nation continues to record a surge in the number of Covid-19 cases

Major drug makers pause operations in Russia amid Ukraine invasion

A slew of drugmakers, including from US, France, Germany, Switzerland, and UK have halted exports of non-essential medicines to Russia, due to Ukraine war, while continuing supply of critical medicine

Aurobindo, Sun Pharma recall products in US market for defaulting norms

Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to deviation from standard manufacturing norms.

Price war rages as pharma firms despatch Covid-19 antiviral pill

Competitive pricing among firms keeps rates at Rs 1,400-2,490 for full treatment

Johnson & Johnson plans to split into drug and consumer companies

The health-care giant will split off its consumer division in 18 to 24 months, the company said in a statement

Drug maker Lupin reports consolidated net loss of Rs 2,098 cr in Q2

Drug maker Lupin on Thursday reported a consolidated net loss

Active pharmaceutical ingredients sales momentum begins to normalise

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players

Domestic drug market bounces back in Dec, ends CY20 with 3.1% growth

Clocks 8.5% growth in December, up sharply from November's 1% due to revival in volume growth

PE firm PAG-led group to buy pharma firm Anjan Drug for undisclosed sum

Target company makes and supplies active pharmaeutical ingredients in the central nervous system space to some of the world's largest drug makers

EU in talks with drugmakers to secure potential Covid-19 vaccines: Report

The multiple talks confirm the bloc's more assertive stance on procuring potential Covid-19 shots and drugs after Washington's early moves in securing promising treatments and vaccines

Drug makers want free hand in pricing and advertising OTC drugs

Currently there are no specific regulations governing the sale of OTC products and this impacts both patient safety and access, says OPPI